ANZUP at ASCO 2025 – BCG+MM

Mitomycin plus (BCG), as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial (ANZUP 1301)

Prof Dickon Hayne presented the overall survival results of the BCG-MM trial that offers hope for people diagnosed with high-risk non-muscle invasive bladder. The findings show that Bacillus Calmette-Guérin or BCG – that works to stimulate the body’s immune system, when used in combination with mitomycin chemotherapy is a safe and effective alternative to BCG alone, with the added benefit of requiring 40 percent fewer BCG doses, and evidence suggests that those at highest risk of recurrence may benefit even more from the combination approach. Patients receiving the combination were more likely continue the treatment course than those on BCG alone. In a time of a global shortage of BCG, the results of this trial could help to expand access to this treatment ensuring more patients get access to the care they deserve.